Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc (NASDAQ:RPRX), filed a Form 4 on November 18, 2026, disclosing the sale of a combined 257,122 Class A Ordinary Shares across multiple indirect vehicles on November 16 and 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • 10b5-1 plan: All reported transactions were effected pursuant to a 10b5-1 plan adopted by Coyne on August 6, 2026, according to the filing.
  • Nov. 16 sales: 135,249 shares were disposed of by TPC RP 2021, LLC at a weighted average price of $68.8681; 90,165 shares were disposed of by TPC RP, LLC at a weighted average price of $68.868; and 7,122 shares were disposed of by TPC RP EPA1 LLC at a weighted average price of $68.868.
  • Nov. 17 sales: 14,751 shares were disposed of by TPC RP 2021, LLC and 9,835 shares by TPC RP, LLC, both at a weighted average price of $68.3047 per share.
  • Remaining indirect holdings: Following the transactions, the filing shows 24,170 shares held indirectly by a Spouse's IRA, 23,270 shares held indirectly by an IRA, and 1,450 shares held indirectly by a Spouse, with zero shares remaining in TPC RP 2021, LLC and TPC RP, LLC.
  • Direct holdings: 1,500 Class A Ordinary Shares are held directly by the reporting person following the reported transactions.
  • Additional interests: The filing states that Coyne and family vehicles controlled by him hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,198,180 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,788,777 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Coyne's Multi-Vehicle Share Dispositions Under Rule 10b5-1 Plan

According to the filing, all five reported sale transactions were executed under a Rule 10b5-1 plan that Coyne adopted on August 6, 2026. The sales took place across two consecutive trading days and were carried out through three indirectly held entities: TPC RP 2021, LLC, TPC RP, LLC, and TPC RP EPA1 LLC. The filing notes that each reported price is a weighted average, with November 16 sales ranging from $68.35 to $69.97 per share (for the two larger lots) and from $68.36 to $69.97 per share for the TPC RP EPA1 LLC lot, while November 17 sales ranged from $67.79 to $68.75 per share.

The filing states that the holder of the shares undertakes to provide full information on the number of shares sold at each separate price within the stated ranges to the issuer, any security holder, or SEC staff upon written request. Following the two-day disposal, both TPC RP 2021, LLC and TPC RP, LLC show a remaining balance of zero shares in the filing's beneficial ownership table, while TPC RP EPA1 LLC had its entire reported position of 7,122 shares disposed of on November 16.

Beyond the transacted positions, the filing discloses that Coyne and family vehicles controlled by him hold limited partnership interests exchangeable into 6,198,180 Class A Ordinary Shares of Royalty Pharma plc, as well as Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,788,777 Class A Ordinary Shares, the latter being subject to vesting conditions. The Form 4 was signed by Sean Weisberg as Attorney-in-Fact for Terrance P. Coyne on November 18, 2026.

What Was Disclosed

Royalty Pharma plc's CFO Terrance P. Coyne reported the sale of 257,122 Class A Ordinary Shares through three indirectly held entities on November 16 and 17, 2026, all pursuant to a Rule 10b5-1 plan adopted August 6, 2026, with weighted average sale prices between $68.3047 and $68.8681.